Dtsch Med Wochenschr 2016; 141(16): 1158-1160
DOI: 10.1055/s-0042-107452
Klinischer Fortschritt
Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Primäre und sekundäre glomeruläre Erkrankungen

Primary and secondary glomerular diseases
Rainer Birck
1   Praxis für Nieren- und Hochdruckerkrankungen Lindau
,
Bernhard Banas
2   Abteilung für Nephrologie, Universitätsklinikum Regensburg
3   KfH-Nie Klinik für Innere Medizin II, Caritas-Krankenhaus St. Josef Regensburg
4   KfH-Nierenzentrum, Regensburg
,
Urs Benck
5   V. Medizinische Klinik, UMM Universitätsmedizin Mannheim
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
10. August 2016 (online)

    Lizenzen und Reprints

Schlüsselwörter

ANCA-assoziierte Vaskulitis - IgA-Nephropathie - Lupusnephritis - Therapie

Keywords

ANCA-associated vasculitis - IgA-Nephropathy - Lupus nephritis - treatment
 

  • Literatur

  • 1 Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11
    CrossrefGoogle Scholar
  • 2 Berden A, Goceroglu A, Jayne D et al. Diagnosis and management of ANCA associated vasculitis. BMJ 2012; 344: e26
    CrossrefGoogle Scholar
  • 3 Lally L, Spiera R. B-cell-targeted therapy in systemic vasculitis. Cur Op Rheum 2016; 28: 15-20
    Google Scholar
  • 4 Jones RB, Furuta S, Tervaert JW et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015; 74: 1178-1182
    CrossrefGoogle Scholar
  • 5 Guillevian L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771-1780
    CrossrefGoogle Scholar
  • 6 Harper L, Morgan MD, Walsh M et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71: 955-960
    CrossrefGoogle Scholar
  • 7 Rauen T, Eitner F, Fitzner C et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med 2015; 373: 2225-2236
    CrossrefPubMedGoogle Scholar
  • 8 Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol 2011; 31: 349-360
    CrossrefGoogle Scholar
  • 9 Smerud HK, Bárány P, Lindström K et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011; 26: 3237-3742
    CrossrefGoogle Scholar
  • 10 Pharmalink AB. The NEFIGAN trial. http://www.nefigan.net/ (letzter Zugriff: 2.6.2016)
    Google Scholar
  • 11 Houssiau FA, Vasconcelos C, D‘Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131
    CrossrefPubMedGoogle Scholar
  • 12 Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112
    CrossrefPubMedGoogle Scholar
  • 13 Chen W, Tang X, Liu Q et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kid Dis 2011; 57: 235-244
    CrossrefGoogle Scholar
  • 14 Li X, Ren H, Zhang Q et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012; 27: 1467-1472
    CrossrefGoogle Scholar
  • 15 Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015; 162: 18-26
    CrossrefPubMedGoogle Scholar